Dr. Omer Kucuk, MD

Dr. Kucuk practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Kucuk's NPI, 1255388948, was assigned on May 28, 2006. Dr. Kucuk holds Georgia license 061470.

Dr. Kucuk's primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Kucuk's primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Kucuk is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Kucuk to 3 more hospitals, 1 clinical lab, 1 ambulatory surgery center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kucuk practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kucuk's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Kucuk's licenses on file in 2 states: Georgia and Michigan.

CMS data shows 633 Medicare services from Dr. Kucuk across 2 procedure codes in 2024, all of them office visits, for 233 Medicare patients. Medicare paid $45,603 for them. Every service was in an office.

CMS counts 233 Medicare patients who saw Dr. Kucuk in 2024. The largest group is 75 to 84, with 105 patients. 75% of them have cancer, and 75% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kucuk's median patient age at 77, with 10% women.

In 2024, Dr. Kucuk wrote 1,333 Medicare Part D claims for 233 patients. 72% of them were for generic drugs. CMS names the drug for 1,250 of them, across 18 drugs with 11 or more claims each, at $4,058,635 in total drug cost. In 2023, CMS named 992 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Kucuk for performance year 2024, reported through an alternative payment model (APM). Dr. Kucuk accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kucuk as offering telehealth.

Dmand AI links 47 papers to Dr. Kucuk, published from 2018 to 2025. 2021 was the busiest year, with 13. The most frequent topics are Immune Checkpoint Inhibitors, Prostatic Neoplasms and Carcinoma, Renal Cell. Dr. Kucuk has published most often in Oncologist. Dr. Kucuk's most frequent co-authors are Bradley Curtis Carthon, MD, PhD, Bassel Nazha, MD, MPH and Mehmet Asim Bilen, MD.

CMS Open Payments shows 61 general payments to Dr. Kucuk from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. Novartis Pharmaceuticals Corporation paid the most, $14,524.